现代中西医结合杂志2025，Vol.34Issue(16)：2202-2206,2214,6.DOI:10.3969/j.issn.1008-8849.2025.16.002
非小细胞肺癌免疫相关不良反应预测因素的研究
Predictors of immune-related adverse events in non-small cell lung cancer
摘要
Abstract
Objective It is to analyze the influencing factors for immune-related adverse reactions(IRAs)in patients with non-small cell lung cancer(NSCLC)after treatment with immune checkpoint inhibitor(ICI).Methods The data of 218 NSCLC patients treated with programmed death-protein/programmed death-ligand 1(PD-L1)monoclonal antibodies combined with chemotherapy in Hebei General Hospital from September 1,2022,to August 31,2024 were retrospectively analyzed.The patients were divided into IRAr group and non-IRAr group according to the occurrence of IRAs.The clinical baseline characteristics of patients were compared between the two groups,the influencing factors for the occurrence of IRAr in patients after treatment with ICIs were analyzed by multivariate Logistic regression model.Results There were 98 patients in the IRAr group and 120 patients in the non-IRAr group,there were significant differences in body mass index(BMI),neutrophil count,lymphocyte count,platelet count,neutrophil-to-lymphocyte ratio(NLR),platelet-to-lymphocyte ratio(PLR),prognostic nutritional index(PNI)and the levels of hemoglobin(Hb),albumin(ALB),lactate dehydrogenase(LDH)and C-reactive protein(CRP)between the two groups(all P<0.05).Multivariate logistic regression analysis re-vealed that lower levels of Hb and ALB,higher levels of PLR,LDH and CRP before treatment were independent risk fac-tors for IRAr after treatment with ICI(all P<0.05).Conclusion Lower levels of Hb and ALB,higher levels of PLR,LDH and CRP before treatment are independent risk factors for the occurrences of immune-related adverse reactions in pa-tients with non-small cell lung cancer after treatment with immune checkpoint inhibitor.It is recommended that patients need systematic assessment of nutritional and anemia status before starting immunotherapy,and need dynamic monitoring of inflammatory markers to reduce the risks of occurrences of immune-related adverse events.关键词
非小细胞肺癌/免疫检查点抑制剂/影响因素Key words
non-small cell lung cancer/immune checkpoint inhibitors/influencing factors分类
医药卫生引用本文复制引用
彭丽丽,田磊,阎晓路,王振祥,郝立元,刘苗苗,郭亚鹏,崔玉洁,臧玉芹,步玉晴,贺丽亚..非小细胞肺癌免疫相关不良反应预测因素的研究[J].现代中西医结合杂志,2025,34(16):2202-2206,2214,6.基金项目
河北省医学科学研究课题计划项目(20230370) （20230370）
